1-6 of 6
Peter Buhl Jensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A182: Targeting the topoisomerase I enzyme in cancer cells with acquired resistance to SN-38

Jan Stenvang, Niels Frank Jensen, Haatisha Jandu, Steen Knudsen, Keli Agama, Thomas Jensen, Anker Hansen, Peter Buhl Jensen, Yves Pommier, Mark Cushman, Nils Brünner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A182.
https://doi.org/10.1158/1535-7163.TARG-15-A182
Published: 01 December 2015
View article titled, Abstract A182: Targeting the topoisomerase I enzyme in cancer cells with acquired resistance to SN-38
Journal Articles

Abstract C168: A two stage prospective clinical trial with irofulven treatment targeting a selected subgroup of castration- and docetaxel resistant prostate cancer patients

Steen Knudsen, Thomas Jensen, Anker Hansen, Ulla Buhl, Annie Rasmussen, Bruce Pratt, Arun Asaithambi, Nils Brünner, Peter Buhl Jensen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C168.
https://doi.org/10.1158/1535-7163.TARG-15-C168
Published: 01 December 2015
View article titled, Abstract C168: A two stage prospective clinical trial with irofulven treatment targeting a selected subgroup of castration- and docetaxel resistant prostate cancer patients
Journal Articles

Abstract B71: DEN-50R - establishment of a novel and unique cell line based drug screening platform for cancer treatment

Jan Stenvang, Jose Moreira, Niels Frank Jensen, Signe Lykke Nielsen, Torben Orntoft, Ulrik Lassen, Cathrine Nordgaard, Stine Ninel Hansen, Haatisha Jandu, Anna Vind, Maria Andreasen, Camilla Cederbye, Julie Noer, Thiago Lima, Birgitte Martine Viuff, Soeren Brunak, Thomas Skoet Jensen, Peter Buhl Jensen, Joergen Drejer, Henrik Ditzel, Nils Brünner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B71.
https://doi.org/10.1158/1535-7163.TARG-15-B71
Published: 01 December 2015
View article titled, Abstract B71: DEN-50R - establishment of a novel and unique cell line based drug screening platform for cancer treatment
Journal Articles

A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor

Uffe Høgh Olesen, Annemette V. Thougaard, Peter Buhl Jensen, Maxwell Sehested
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1609–1617.
https://doi.org/10.1158/1535-7163.MCT-09-1130
Published: 09 June 2010
View article titled, A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor
Open the PDF for A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor in another window
Journal Articles

Phase II multicenter tial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with relapsed ovarian cancer

Neil Finkler, Don Dizon, John Micha, Patricia Braly, Ulrik Lassen, SA Sngelholm, Rosalind Glasspool, Elizabeth Crowley, Shu-Xia Li, Peter Buhl-Jensen, Richard Penson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C223.
Published: 01 November 2007
View article titled, Phase II multicenter tial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with relapsed ovarian cancer
Journal Articles

A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.

Rhoda Molife, James Lee, Daniel Petrylak, George Blumenschein, Ulrik Lassen, Jayme Clark, Timothy Yap, Elin Rowen, Jooern Ang, Elizabeth Crowley, Anne Clarke, Thomas Hawthorne, Peter Buhl-Jensen, Johann de Bono, Wm Kelly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B134.
Published: 01 November 2007
View article titled, A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.